First Bank & Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

First Bank & Trust’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-15	Closed	-$4K	–	493
2022 Q2	$4K	Hold	15	–	–	﹤0.01%	398
2022 Q1	$4K	Hold	15	–	–	﹤0.01%	419
2021 Q4	$3K	Buy	+15	New	+$2.92K	﹤0.01%	433
2019 Q3	–	Sell	-9	Closed	-$2K	–	494
2019 Q2	$2K	Buy	+9	New	+$1.57K	﹤0.01%	420

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Bank & Trust's VRTX Position: Q3 2022 in Review

First Bank & Trust sold out of Vertex Pharmaceuticals (VRTX) in Q3 2022, closing a stake of 15 shares — an estimated $4K sold.

First Bank & Trust first reported a position in VRTX in Q2 2019 and held it in 4 quarters. The position peaked at $4K in Q2 2022. 1,124 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.

First Bank & Trust reported no remaining Vertex Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
First Bank & Trust sold 15 Vertex Pharmaceuticals shares in Q3 2022, an estimated $4K.
First Bank & Trust first reported a position in Vertex Pharmaceuticals in Q2 2019 and held it in 4 quarters.
First Bank & Trust's Vertex Pharmaceuticals position peaked at $4K in Q2 2022.
1,124 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.

Based on First Bank & Trust's 13F filing for Q3 2022, filed 28 Oct 2022.